Germany - Analgesics

Description

Establishment of a DBS for the procurement of medicinal products of the indication group antibiotics in various pharmaceutical forms.The DBS is carried out in 2 phases:1. Establishment and administration of a bidder poolThe DBS is established for the duration specified in No. 1.2 and for the service spectrum antibiotics. The procedure is carried out exclusively electronically. The contracting authority shall create a pool of bidders.Any interested party may activate participation in the procedure and submit a request to participate at any time during the DBS. Any interested party that meets the eligibility criteria published in the contract notice is included in the bidder pool. He thus becomes a potential bidder and may submit a bid in the subsequent individual awards.The bidder pool is not limited in size. Any qualified participant will be included in the bidder pool.2. Bidding PhaseActual procurements will be made in the form of individual awards as required by the contracting authority during the bidding phase. The contracting authority decides on the timing or number of individual awards. It is expressly pointed out that there is no obligation on the part of the contracting authority to carry out individual awards.On the occasion of the individual award, the contracting authority invites all participants in the bidder pool admitted to the DBS to submit a bid and informs them of the specific terms of the contract (e.g. quantity, delivery time, place of delivery, award criteria, etc.), provided these have not already been published in the notice.By submitting a bid, the bidder declares that no changes will be made to the suitability criteria. The content of the tenders received will be examined on the basis of the award criteria published. The bidder with the most economical bid to be determined on the basis of the notified award criteria will be awarded the contract.Participants admitted to the DBS bidder pool are not obliged to submit a bid in the context of the individual awards.Participants must always keep themselves informed of the current status of the award procedure (the individual award). Any extensions of deadlines, applicant questions with the corresponding answers or other updates and changes must be retrieved independently by the participant on the federal e-award platform. Any changes will be announced immediately by the contracting authority.
It is intended to contract a total of approx. 29,000,000 units of, for example, the following active substances of the indication groups antidotes, corticoids, narcotics, analgesics and anticoagulants within the framework of the DBS.The quantities stated (total requirement = term of the DBS; requirement 2021 = anticipated annual requirement 2021) represent forecast values in each case.It is expressly pointed out that further active substances may be placed by individual awards.Legend: AMP = Ampoule, EA = Piece, TU = Tube, BT = Bottle, PR = Pair, IE = International UnitAntidota: "1. atropine sulfate injection (active ingredient ATROPIN 0.5 MG/ML), total requirement approx. 91 800 AMP, requirement 2021 approx. 48 500 AMP,2. dimercaptopropane sulfonic acid (active ingredient dimercaptopropane sulfonic acid 10 MG), total requirement approx. 50 000 EA, requirement 2021 0 EA,3. flumazenil injection (active ingredient flumazenil 0.5 MG/5ML), total requirement approx. 33 000 AMP, requirement 2021 approx. 21 400 AMP,4. naloxone hydrochloride injection (active ingredient naloxone 0.4 MG/ML), total requirement approx. 87 400 AMP, requirement 2021 approx. 65 200 AMP.Corticoids:1. prednisolone sodium succinate for injection (active ingredient prednisolone 250 MG), total requirement approx. 110 200 PR, requirement 2021 approx. 85 300 PR,2. prednisolone tablet (active ingredient prednisolone 5 MG, divisible), total requirement approx. 246 500 EA, requirement 2021 0 EA,3. Prednisolone tablet (active ingredient Prednisolone 50 MG, quarterable), total requirement approx. 152 000 EA, requirement 2021 approx. 120 EA,4. Prednisone tablet (active ingredient Prednisone 20 MG), total requirement approx. 144 200 EA, requirement 2021 approx. 7 200 EA." It is intended to contract a total of approx. 29,000,000 units of, for example, the following active ingredients of the indication groups antidotes, corticoids, narcotics, analgesics and anticoagulants within the framework of the DBS.The quantities stated (total requirement = term of the DBS; requirement 2021 = anticipated annual requirement 2021) represent forecast values in each case.It is expressly pointed out that further active ingredients may be placed through individual awards.Legend: AMP = ampoule, EA = piece, TU = tube, BT = bottle, PR = pair, IE = international unitNarcotics: "1. Bupivacaine m. Epinephrine (active ingredient 1 Bupivacaine hydrochloride 0.5%/ML, active ingredient 2 Epinephrine hydrogen tartrate 0.0005 %), total requirement approx. 199 700 AMP, requirement 2021 approx. 97 900 AMP,2. Butylscopolaminium bromide tablet (active ingredient Butylscopolaminium bromide 10 MG/TBL), total requirement approx. 1 324 800 EA, requirement 2021 approx. 106 800 EA,3. Lorazepam Plaette (active ingredient Lorazepam 1 MG/SMT), total requirement approximately 328 800 EA, requirement 2021 approximately 195 600 EA,4. Midazolam Hydrochloride Injection (active ingredient MIDAZOLAM 5 MG/5ML), total requirement approximately 105 100 AMP, requirement 2021 approximately 65 900 AMP,5. Propofol Injection (active ingredient Propofol 10 MG/ML), total requirement approximately 101 800 AMP, requirement 2021 approximately 32 400 AMP." It is intended to contract a total of approx. 29,000,000 units of, for example, the following active ingredients of the indication groups antidotes, corticoids, narcotics, analgesics and anticoagulants within the framework of the DBS.The quantities stated (total requirement = term of the DBS; requirement 2021 = anticipated annual requirement 2021) represent forecast values in each case.It is expressly pointed out that further active ingredients may be placed through individual awards.Legend: AMP = Ampoule, EA = Piece, TU = Tube, BT = Bottle, PR = Pair, IE = International UnitAnalgesics: "1. Acetylsalicylic acid tablets (active ingredient acetylsalicylic acid 500 MG/TBL), total requirement approx. 294 200 EA, requirement 2021 approx. 48 300 EA,2. Dexketoprofentrometamol tablets (active ingredient dexketoprofen 25 MG/TBL), total requirement approx. 378 300 EA, requirement 2021 0 EA,3. Diclofenacdiethylamine gel (active ingredient diclofenac 9.31 MG/1G), total requirement approx. 148 800 TU, requirement 2021 approx. 4 900 TU,4. Diclofenac sodium capsules (active ingredient diclofenac 69.82 MG/KPS), total requirement approx. 986 800 EA, requirement 2021 0 EA,5. diclofenac sodium effervescent tablet (active ingredient diclofenac 46.50 MG/BTBL), total requirement approx. 905 400 EA, requirement 2021 0 EA,6. ibuprofen tablets (active ingredient ibuprofen 400 MG/TBL, divisible), total requirement approx. 16 203 500 EA, requirement 2021 approx. 332 800 EA,7. metamizole sodium injection (active ingredient metamizole 2215.41 MG/5ML), total requirement approx. 63 900 AMP, requirement 2021 approx. 58 900 AMP,8. paracetamol tablet (active ingredient paracetamol 500 MG/TBL), total requirement approx. 1 854 000 EA, requirement 2021 approx. 290 300 EA." It is intended to contract a total of approx. 29,000,000 units of, for example, the following active ingredients of the indication groups antidotes, corticoids, narcotics, analgesics and anticoagulants within the framework of the DBS.The quantities stated (total requirement = term of the DBS; requirement 2021 = anticipated annual requirement 2021) represent forecast values in each case.It is expressly pointed out that further active ingredients may be placed through individual awards.Legend: AMP = ampoule, EA = piece, TU = tube, BT = bottle, PR = pair, IE = international unitAnticoagulants: "1. acetylsalicylic acid tablet, DAB (active ingredient acetylsalicylic acid 100 MG), total requirement approx. 536,500 EA, requirement 2021 approx. 6 000 EA,2. enoxaparin sodium injection (active ingredient enoxaparin sodium 40 MG), total requirement approx. 309 600 EA, requirement 2021 approx. 44 800 EA,3. heparin sodium injection (active ingredient heparin sodium 25000 IU), total requirement approx. 95 400 BT, requirement 2021 approx. 70 500 BT,4. rivaroxaban tablets (active ingredient rivaroxaban 20 MG), total requirement approx. 90 300 EA, requirement 2021 approx. 2 400 EA."

Opportunity closing date

21 April 2025

Value of contract

to be confirmed